Of the examined genes, only ATG4D had a significant correlation with DMFS in the total cohort of NPC patients and the EBV-positive subgroup, indicating that patients with heightened ATG4D expression levels experienced improved DMFS outcomes relative to those with reduced ATG4D expression. This evidence concerns the gene ATG4D and nasopharyngeal carcinoma.